Morphic Holding Investor Relations Material
Latest events
Study Update
Morphic Holding
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Morphic Holding Inc
Access all reports
Morphic Holding Inc., a biopharmaceutical company, specializes in the discovery and development of oral small-molecule integrin therapeutics. These treatments are aimed at addressing a variety of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. A key focus of their research is on MORF-057, an α4β7 integrin inhibitor designed to modulate inflammation, currently in clinical trials for treating inflammatory bowel disease. Morphic's pipeline also explores integrin targets for other gastrointestinal indications, myelofibrosis, and solid tumors among others. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
MORF
Country
🇺🇸 United States